Metabolic disease alliance with MedImmune

Metabolic disease alliance with MedImmune
·         Focus on innovative diabetes therapy

  • €5 million upfront payment, up to €254 million milestones and royalties
  • Evotec's first commercial agreement in the field of beta cell regeneration

Hamburg, Germany - 15 December 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells.  The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.

The agreement triggers an upfront payment of € 5 million.  Further on, additional deferred payments including potential milestone payments of up to € 254 million as well as royalties are agreed.  The milestone payments will be due upon achievement of certain clinical as well as regulatory and commercial events.  Further milestone payments may be achieved with the approval of additional indications and programs.  Evotec will also receive research payments to support further in vivo and in vitro pharmacology efforts conducted in collaboration with MedImmune.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "The loss of insulin producing beta cells is tightly linked to the development of diabetes.  Using a unique screening approach for beta cell regeneration targets, we have identified and validated novel and highly relevant biological factors.  The most advanced factor has demonstrated efficacy in animal models of beta cell regeneration in particular increasing the functional beta cell mass and thereby improving and restoring glycemic control."  Dr. Dohrmann continued: "MedImmune is a leader in biopharmaceutical research with cutting edge protein production and engineering capabilities and thus a perfect partner for Evotec.  Together we intend to generate a pipeline of biological factors that have the potential to prevent or reverse disease progression, and confer optimal glycemic control in patients. "

Given the innovative character of the alliance Evotec invites you to join a brief conference call.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.